CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
Antibacterial, Antifungal, Corticosteroid. Gramicidin 0.25 mg/g, Neomycin Sulphate 2.5 mg/g, Nystatin 100000 IU/g, Triamcinolone 1 mg/g. CREAM: 5, 15 g. Apply 2-3 x dly.
Allerg. and infect. dermatit., eczema,
cutan. candidiasis, anogenital prurit.
C/I: T.B., herpes simplex, vaccinia,
varicella, lesions not suscept. to nystatin.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
Selective estrogen receptor modulators. Raloxifene 60 mg. TABS.: 30. 1 tab×1/d. with /without food at the same time a day. See lit. .
Tmt. of osteoporosis in post menopaus. women.
Prevent. of osteoporosis in post menopaus. women.
Reduct.in risk of invas. breast canc. in postmenopaus. women with osteoporosis.
Reduc. in risk of invas. breast canc. in postmenopaus. women at high risk for invas. breast canc.
Pts. who are on anticoag. ther.
Hist./present DVT, PE or Retinal vein thrombos.
Pts. who are immobile for a long period of time.
Monoclonal Antibody. Romosozumab 90 mg / mL 90mg/ml. PRE-FILL. SYR. (sol. for S.C. inj.):2. 210 mg admin. S.C. in the abdo., thigh or upper arm. admin. once every month.
The tmt. duration is 12 mnthly. doses.
Pts. should be adequat. supplem. with calcium & vit. D during tmt.
If the dose is missed, admin.as soon as it can be rescheduled. Thereafter, the dose can be scheduled every month from the date of the last dose.
Tmt. of severe osteoporosis in postmenop. women at high risk for fract., defined as a history of osteoporotic fract., or multiple risk fact. for fracture; or pts. who have failed or are intoler. to other available osteoporosis ther.
Hypocalcem., Pre-exist. hypocalc.
Pts. who experiences a MI or stroke during ther.
Pts. who had a MI or stroke within the preceding year.
Analgesic/Antipyretic.. Dipyrone 500mg / ml (20 drops). BOTTLE (oral dr.): 20ml.
Adult. & adolesc.>15 yrs. (wt.>53 kg): 20-40 dr., up to 3 times a d.Child.:
3-11 mnths. (5-8 kg) 2-4 dr., up to 3/d.
1 - 3 yrs. (9 – 15kg) 3 - 10 dr., up to 3/d.4 - 6 yrs. (16 – 23kg) 5 - 15 dr., up to 3/d.
7 - 9 yrs. (24 – 30 kg) 8 - 20 dr., up to 3/ d.
10 - 12 yrs. (31 – 45 kg) 10 - 30 dr., up to to 3/d.
13 - 14 yrs. (46 – 53 kg) 15 - 35 dr., up to 3/d. Should be taken at 6-8 hr. intervals. Not more than three doses in 24 hrs.
For relief of moder.- sev. pain, such as headache, toothache, menstrual pain, and for reducing high fever that does not respond to other tmt. measures.
Engineered Autologous T Cell Immunotherapy product. Axicabtagene Ciloleuce . BAG CRYOSTORE (Sol. for IV infus.):1. Dosage must be ajust. individ. See lit.
Tmt. of adult pts. with relapsed or refract. diffuse large B cell lymphoma. (DLBCL) and primary mediastin. large B cell lymphom. (PMBCL), after two or more lines of system. ther.
Limitation of Use: YESCARTA is not indicated for the tmt. of pts. with prim. or second. CNS lymphoma.
Contraindications of the lymphodepleting chemother.must be considered.
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
Colony Stimulating Factor. Filgrastim 300 mcg/0.5 ml, 480mcg/0.5ml. PREF.SYR. (sol. for inj. or infus.):1,3,5,10×. Dosage ajust. individ. accord. pt. med. condition.
Indicated for the reduct. in the duration of neutropen. and the incidence of febrile neutropen. in pts. treated with established cytotoxic chemother. for malignan. (with the exception of chronic myeloid leukaem. and myelodysplastic syndr.) and for the reduc. in the duration of neutropen. in pts. underg. myeloablative therapy followed by bone marrow transplantat. consid.to be at incr. risk of prolong. severe neutropen. The safety and efficacy of StimoFil are similar in adults and child. receiv. cytotox. chemother.
Indic. for the mobilisation of peripher. blood progenitor cells (PBPCs).
In pts., child. or adult. with severe congenit., cyclic, or idiopath. neutropen. with an absolute neutrophil count (ANC) of ≤ 0.5 x 109 /L, and a history of severe or recur. infections, long term admin. of StimoFil is indic.to incr. neutrophil counts and to reduce the incidence and durat. of infec.-related events.
Tmt. of persist. neutropen. (ANC less than or equal to 1.0 x 109/L) in pts. with advanced HIV infec., in order to reduce the risk of bacter. infections when other options to manage neutropen. are inappropr.